Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Enseval Putera Megatrading

BST:FEK
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FEK
BST
IDR6,365B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

PT Enseval Putera Megatrading Tbk, together with its subsidiaries, engages in the distribution and supply of pharmaceutical products in Indonesia. The last earnings update was 153 days ago. More info.


Add to Portfolio Compare Print
  • Enseval Putera Megatrading has significant price volatility in the past 3 months.
FEK Share Price and Events
7 Day Returns
6.9%
BST:FEK
8.4%
DE Healthcare
9.9%
DE Market
1 Year Returns
-31.6%
BST:FEK
-25.6%
DE Healthcare
-17.5%
DE Market
FEK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Enseval Putera Megatrading (FEK) 6.9% -10.5% -22.3% -31.6% -37.1% -55.2%
DE Healthcare 8.4% -16.2% -21.1% -25.6% -43.3% -32%
DE Market 9.9% -16.6% -24.8% -17.5% -24.5% -28.1%
1 Year Return vs Industry and Market
  • FEK underperformed the Healthcare industry which returned -25.6% over the past year.
  • FEK underperformed the Market in Germany which returned -17.5% over the past year.
Price Volatility
FEK
Industry
5yr Volatility vs Market

Value

 Is Enseval Putera Megatrading undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Enseval Putera Megatrading to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Enseval Putera Megatrading.

BST:FEK Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-09-30) in IDR IDR 90.000000
Payout Ratio Company Filings (2019-09-30) 252.3%
Discount Rate (Cost of Equity) See below 5.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:FEK
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 7.9%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.66
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.657 (1 + (1- 25%) (0%))
0.77
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (0.8 * 7.85%)
5.89%

Discounted Cash Flow Calculation for BST:FEK using Dividend Discount Model Model

The calculations below outline how an intrinsic value for Enseval Putera Megatrading is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

BST:FEK Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= IDR90 / (5.89% - -0.39%)
IDR0
BST:FEK Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:FEK represents 4.0E-5x of IDX:EPMT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
4.0E-5x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (IDR) x Listing Adjustment Factor
= IDR 1,433.12 x 4.0E-5
€0.05
Value per share (EUR) From above. €0.05
Current discount Discount to share price of €0.09
= -1 x (€0.09 - €0.05) / €0.05
-64%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Enseval Putera Megatrading is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Enseval Putera Megatrading's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Enseval Putera Megatrading's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:FEK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in IDR IDR241.67
IDX:EPMT Share Price ** IDX (2020-03-31) in IDR IDR2350
Germany Healthcare Industry PE Ratio Median Figure of 9 Publicly-Listed Healthcare Companies 27.51x
Germany Market PE Ratio Median Figure of 399 Publicly-Listed Companies 16.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Enseval Putera Megatrading.

BST:FEK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= IDX:EPMT Share Price ÷ EPS (both in IDR)

= 2350 ÷ 241.67

9.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Enseval Putera Megatrading is good value based on earnings compared to the DE Healthcare industry average.
  • Enseval Putera Megatrading is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Enseval Putera Megatrading's expected growth come at a high price?
Raw Data
BST:FEK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 9.72x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.22x
Germany Market PEG Ratio Median Figure of 255 Publicly-Listed Companies 1.18x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Enseval Putera Megatrading, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Enseval Putera Megatrading's assets?
Raw Data
BST:FEK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in IDR IDR2,224.84
IDX:EPMT Share Price * IDX (2020-03-31) in IDR IDR2350
Germany Healthcare Industry PB Ratio Median Figure of 14 Publicly-Listed Healthcare Companies 1.13x
Germany Market PB Ratio Median Figure of 571 Publicly-Listed Companies 1.43x
BST:FEK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= IDX:EPMT Share Price ÷ Book Value per Share (both in IDR)

= 2350 ÷ 2,224.84

1.06x

* Primary Listing of Enseval Putera Megatrading.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Enseval Putera Megatrading is good value based on assets compared to the DE Healthcare industry average.
X
Value checks
We assess Enseval Putera Megatrading's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Enseval Putera Megatrading has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Enseval Putera Megatrading expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Enseval Putera Megatrading has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.4%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Enseval Putera Megatrading expected to grow at an attractive rate?
  • Unable to compare Enseval Putera Megatrading's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Enseval Putera Megatrading's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Enseval Putera Megatrading's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:FEK Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 9.4%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 5.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:FEK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in IDR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:FEK Past Financials Data
Date (Data in IDR Millions) Revenue Cash Flow Net Income *
2019-09-30 21,957,169 67,516 654,594
2019-06-30 21,517,450 176,457 683,010
2019-03-31 20,978,645 549,620 670,328
2018-12-31 20,604,487 543,779 653,064
2018-09-30 20,232,612 551,584 649,403
2018-06-30 19,957,177 87,312 557,821
2018-03-31 19,771,034 272,235 542,457
2017-12-31 19,669,097 -203,607 517,671
2017-09-30 19,560,663 -296,839 516,699
2017-06-30 19,341,958 21,030 537,375
2017-03-31 19,159,057 -30,137 522,852
2016-12-31 18,936,241 244,822 556,026

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Enseval Putera Megatrading is high growth as no earnings estimate data is available.
  • Unable to determine if Enseval Putera Megatrading is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:FEK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Enseval Putera Megatrading Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:FEK Past Financials Data
Date (Data in IDR Millions) EPS *
2019-09-30 241.67
2019-06-30 252.16
2019-03-31 247.48
2018-12-31 241.10
2018-09-30 239.75
2018-06-30 205.94
2018-03-31 200.27
2017-12-31 191.12
2017-09-30 190.76
2017-06-30 198.39
2017-03-31 193.03
2016-12-31 205.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Enseval Putera Megatrading will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Enseval Putera Megatrading is trading at Enseval Putera Megatrading'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Enseval Putera Megatrading's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Enseval Putera Megatrading's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Enseval Putera Megatrading's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Enseval Putera Megatrading has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Enseval Putera Megatrading performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Enseval Putera Megatrading's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Enseval Putera Megatrading's year on year earnings growth rate has been positive over the past 5 years.
  • Enseval Putera Megatrading's 1-year earnings growth is less than its 5-year average (0.8% vs 4.8%)
  • Enseval Putera Megatrading's earnings growth has not exceeded the DE Healthcare industry average in the past year (0.8% vs 26%).
Earnings and Revenue History
Enseval Putera Megatrading's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Enseval Putera Megatrading Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:FEK Past Revenue, Cash Flow and Net Income Data
Date (Data in IDR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 21,957,168.82 654,593.81 1,632,735.80
2019-06-30 21,517,450.45 683,009.81 1,589,148.89
2019-03-31 20,978,644.73 670,327.99 1,557,137.49
2018-12-31 20,604,487.29 653,064.16 1,533,390.57
2018-09-30 20,232,611.76 649,403.30 1,515,137.11
2018-06-30 19,957,177.44 557,820.64 1,497,817.26
2018-03-31 19,771,034.05 542,457.11 1,489,607.34
2017-12-31 19,669,096.57 517,670.91 1,460,375.44
2017-09-30 19,560,662.98 516,698.51 1,467,499.33
2017-06-30 19,341,957.95 537,374.80 1,446,716.14
2017-03-31 19,159,056.59 522,851.60 1,461,429.46
2016-12-31 18,936,240.95 556,025.92 1,467,361.79
2016-09-30 18,745,933.01 535,886.45 1,466,157.50
2016-06-30 18,460,101.54 583,881.72 1,454,105.39
2016-03-31 17,810,581.68 574,888.79 1,404,468.12
2015-12-31 17,476,102.96 547,124.23 1,370,659.27
2015-09-30 17,201,932.96 544,325.84 1,298,788.04
2015-06-30 17,209,080.84 517,913.80 1,272,422.65
2015-03-31 17,103,874.60 520,672.96 1,247,466.85
2014-12-31 17,011,549.91 511,064.64 1,231,080.45
2014-09-30 16,946,586.61 529,150.92 1,209,417.27
2014-06-30 16,561,029.97 465,473.13 1,224,615.27
2014-03-31 16,172,599.68 470,720.18 1,155,688.12
2013-12-31 15,623,239.53 464,315.26 1,099,910.61
2013-09-30 14,941,332.52 439,626.88 1,039,822.62
2013-06-30 14,442,263.03 459,430.69 940,366.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Enseval Putera Megatrading has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Enseval Putera Megatrading used its assets more efficiently than the DE Healthcare industry average last year based on Return on Assets.
  • Enseval Putera Megatrading's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Enseval Putera Megatrading's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Enseval Putera Megatrading has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Enseval Putera Megatrading's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Enseval Putera Megatrading's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Enseval Putera Megatrading is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Enseval Putera Megatrading's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Enseval Putera Megatrading's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Enseval Putera Megatrading has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Enseval Putera Megatrading Company Filings, last reported 6 months ago.

BST:FEK Past Debt and Equity Data
Date (Data in IDR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 6,027,438.47 0.00 869,256.16
2019-06-30 5,866,657.03 47,010.55 552,505.58
2019-03-31 5,924,741.24 0.00 1,438,373.18
2018-12-31 5,787,854.88 0.00 1,426,965.59
2018-09-30 5,589,183.54 0.00 1,232,100.97
2018-06-30 5,401,939.11 47,811.62 752,222.92
2018-03-31 5,247,071.69 2,572.53 1,028,172.41
2017-12-31 5,130,769.42 0.00 969,308.27
2017-09-30 4,953,535.83 87,869.11 918,620.29
2017-06-30 4,856,406.58 80,163.31 838,132.78
2017-03-31 4,713,591.31 61,201.66 965,836.35
2016-12-31 4,619,981.23 41,676.86 1,362,945.81
2016-09-30 4,445,859.68 72,950.95 1,269,946.31
2016-06-30 4,327,238.17 105,990.69 916,667.59
2016-03-31 4,198,315.78 174,901.66 1,185,247.97
2015-12-31 4,070,245.69 144,291.64 1,261,914.25
2015-09-30 3,926,338.99 185,699.29 760,491.74
2015-06-30 3,765,502.70 188,632.14 613,640.52
2015-03-31 3,646,977.88 159,247.15 799,922.50
2014-12-31 3,530,725.86 138,623.35 775,790.88
2014-09-30 3,393,665.47 178,354.31 521,263.89
2014-06-30 3,259,564.11 198,519.45 254,041.60
2014-03-31 3,125,347.77 133,521.61 539,931.06
2013-12-31 3,038,851.86 144,840.08 434,659.93
2013-09-30 2,864,460.85 151,897.78 341,129.44
2013-06-30 2,792,911.00 113,027.43 345,483.75
  • Enseval Putera Megatrading has no debt.
  • Enseval Putera Megatrading has no debt compared to 5 years ago when it was 5.2%.
  • Enseval Putera Megatrading has no debt, it does not need to be covered by operating cash flow.
  • Enseval Putera Megatrading has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Enseval Putera Megatrading's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Enseval Putera Megatrading has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Enseval Putera Megatrading's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
3.83%
Current annual income from Enseval Putera Megatrading dividends.
If you bought €2,000 of Enseval Putera Megatrading shares you are expected to receive €77 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Enseval Putera Megatrading's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.68%).
  • Enseval Putera Megatrading's dividend is below the markets top 25% of dividend payers in Germany (4.97%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:FEK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.8%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:FEK Past Annualized Dividends Data
Date (Data in IDR) Dividend per share (annual) Avg. Yield (%)
2019-08-12 90.000 4.319
2019-04-01 90.000 3.783
2018-07-31 5.000 0.257
2018-03-29 5.000 0.265
2017-09-26 5.000 0.209
2017-03-21 5.000 0.176
2016-08-02 5.000 0.172
2016-04-01 5.000 0.182
2015-11-25 5.000 0.183
2015-03-30 5.000 0.190
2014-11-03 0.000 0.000
2014-04-02 0.000 0.000
2013-10-30 2.000 0.054
2013-07-25 2.000 0.058
2013-03-28 2.000 0.066
2012-10-31 95.000 5.002
2012-07-31 95.000 5.773
2012-03-30 95.000 7.730
2011-07-28 5.000 0.649
2011-03-04 5.000 0.626
2010-10-27 27.500 2.579
2010-04-01 27.500 2.650
2009-07-30 27.500 3.252

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Enseval Putera Megatrading's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.7x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Enseval Putera Megatrading's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Enseval Putera Megatrading afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Enseval Putera Megatrading has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Enseval Putera Megatrading's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Djonny Tjahyadi
AGE 55
TENURE AS CEO 4.9 years
CEO Bio

Mr. Djonny Hartono Tjahyadi served as Managing Director of Enseval Putera Megatrading tbk PT. Mr. Tjahyadi served as Marketing Manager in the Ethical Division at PT Kalbe Farma Tbk from 1994 to 1999 and General Manager in PT Erba Farmitalia from 1999 to 2000. He served as Deputy to Marketing Director Ethical Division of PT Kalbe Farma Tbk from 2000 to 2002 and Marketing Director for OTC Medicines Division PT Kalbe Farma Tbk from 2003 to 2006. He has been the President Director of PT Enseval Putera Megatrading Tbk since May 2015. He served as President Director of PT Saka Farma from 2006 to 2008. He has been a Director of PT Enseval Putera Megatrading Tbk since June 2009 and PT. Kalbe Farma Tbk. since May 18, 2015. Mr. Tjahyadi graduated from Bandung School of Economics in 1988. He holds MBA Degree from IMNI School of Management, Jakarta, in 2000.

CEO Compensation
  • Insufficient data for Djonny to compare compensation growth.
  • Insufficient data for Djonny to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Djonny Tjahyadi

TITLE
President Director
AGE
55
TENURE
4.9 yrs

Handi Halim

TITLE
IT, Operational & FA Director

Jos Atmadjaja

TITLE
Sales Director & Director
AGE
49

Yuniati Rachmat

TITLE
HRGA Deputy Director

Sugianto Perusahaan

TITLE
Corporate Secretary
AGE
40
Board of Directors Tenure

Average tenure and age of the Enseval Putera Megatrading board of directors in years:

4.9
Average Tenure
55
Average Age
  • The tenure for the Enseval Putera Megatrading board of directors is about average.
Board of Directors

Djonny Tjahyadi

TITLE
President Director
AGE
55
TENURE
4.9 yrs

Handi Halim

TITLE
IT, Operational & FA Director
TENURE
2.4 yrs

Jos Atmadjaja

TITLE
Sales Director & Director
AGE
49
TENURE
4.9 yrs

Budi Wreksoatmodjo

TITLE
President Commissioner
AGE
61
TENURE
4.9 yrs

Anita Riau Gunawan

TITLE
Independent Commissioner
AGE
74
TENURE
10.8 yrs

Mulia Lie

TITLE
Subsidiary Director

Sanadi Boenyamin

TITLE
Commissioner
AGE
40
TENURE
5.9 yrs

Heru Tjahjadi

TITLE
Subsidiary Director

Taruna Widjaja

TITLE
Subsidiary Director

Made Budiadi

TITLE
Subsidiary Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Enseval Putera Megatrading's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Enseval Putera Megatrading has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

PT Enseval Putera Megatrading Tbk, together with its subsidiaries, engages in the distribution and supply of pharmaceutical products in Indonesia. The company operates in three segments: Pharmaceutical, Consumer Products, and Others. It also distributes medical and laboratory equipment and supplies; and provides health care clinical services. In addition, the company engages in the trading of raw materials for pharmaceutical products; and consumable products for hemodialysis therapy. Further, it offers warehouse facilities, including chiller, cool, and ambient rooms, as well as container chiller as facilities. The company was formerly known as PT Arya Gupta Cempaka and changed its name to PT Enseval Putera Megatrading Tbk in August 1993. The company was founded in 1973 and is headquartered in East Jakarta, Indonesia. PT Enseval Putera Megatrading Tbk is a subsidiary of PT Kalbe Farma Tbk.

Details
Name: PT Enseval Putera Megatrading Tbk
FEK
Exchange: BST
Founded: 1973
IDR357,800,151
2,708,640,000
Website: http://www.enseval.com
Address: PT Enseval Putera Megatrading Tbk
Jalan Pulo Lentut No. 10,
Pulogadung Industrial Estate,
East Jakarta,
Jakarta Raya, 13920,
Indonesia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
IDX EPMT Common Shares Indonesia Stock Exchange ID IDR 09. Aug 1994
BST FEK Common Shares Boerse-Stuttgart DE EUR 09. Aug 1994
Number of employees
Current staff
Staff numbers
4,777
Enseval Putera Megatrading employees.
Industry
Health Care Distributors
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/01 01:48
End of day share price update: 2020/03/31 00:00
Last earnings filing: 2019/10/31
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.